2023年6月24日 · Pegozafermin is a long-acting glycopegylated (pegylated with the use of site-specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development for …

Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity …

2023年6月24日 · Pegozafermin, a long-acting glycopegylated analog of human fibroblast growth factor 21, is in development for the treatment of severe hypertriglyceridemia (SHTG) and …

Pegozafermin (BIO89-100) is a long-acting, glycopegylated FGF21 analog developed for the treatment of nonalcoholic steatohepatitis and hypertriglyceridemia. [1][2][3][4]

2023年9月25日 · Pegozafermin是一种长效糖基化(使用位点特异性糖基转移酶进行聚乙二醇化)成纤维细胞生长因子21 (FGF21)类似物，正在开发用于治疗非酒精性脂肪性肝炎 ...

Pegozafermin (also known as BIO89-100) is a glycoPEGylated analog of fibroblast growth factor 21 (FGF21) under development to treat nonalcoholic steatohepatitis (NASH) and severe …

2023年9月14日 · Background: Pegozafermin is a long-acting glycopegylated (pegylated with the use of site-specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in …

Purpose: Pegozafermin (PGZ) is a long-acting glycopegylated recombinant analog of human fibroblast growth factor 21 (FGF21) being developed for severe hypertriglyceridemia (SHTG) …

6 天之前 · Pegozafermin. Pegozafermin is a long-acting pegylated recombinant FGF21 analog that is useful for the treatment of MASH and severe hypertriglyceridemia . In an ENLIVEN …

Patients were centrally randomised by use of an interactive web response system to receive subcutaneously administered pegozafermin (3, 9, 18, or 27 mg once weekly; 18 or 36 mg once …